Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is expected to have strong potential in the retinal disease market with promising early clinical results for its anti-VEGF therapy, TH103, aimed at addressing the high unmet need for durability of treatment in wet AMD patients. With a focus on patient impact and ethical practices, the company has garnered support from key opinion leaders and analysts project a positive future performance with a current target price of $25. However, there are inherent risks associated with its early stage of development and competition in the market. It is expected to release preliminary data in the first half of 2027.

Bears say

Kalaris Therapeutics is poised to gain a significant market share in the wet AMD market with their potentially superior TH103 drug, which offers longer-lasting and increased anti-VEGF activity. However, the company is facing competition from established drugs like Eylea and Lucentis, and their success will depend on their ability to improve their manufacturing process and gain regulatory approval. The potential for TH103 to treat other VEGF-related retinal diseases also presents a promising opportunity for Kalaris. Additionally, the company's strong patent portfolio adds a layer of protection for potential investors.

Allovir Inc (KLRS) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 4 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.